UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2007
ADVANCED LIFE SCIENCES HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 000-51436 |
| 30-0296543 |
(State or other jurisdiction |
| (Commission |
| (I.R.S. Employer |
of incorporation) |
| File Number) |
| Identification No.) |
|
|
|
|
|
|
| 1440 Davey Road |
|
|
|
| Woodridge, Illinois |
| 60517 |
| (Address of principal executive offices) | (Zip Code) | ||
|
|
| ||
| (630) 739-6744 |
| ||
(Registrant’s telephone number, including area code) |
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On November 6, 2007, Executive Officers of Advanced Life Sciences Holdings, Inc. (the “Company”) announced that the Company expects to release top-line data from Trial CL-05, the second of two pivotal Phase III clinical trials for the use of cethromycin to treat community acquired pneumonia (CAP), within the next two weeks. The exact date of this announcement within the next two weeks is subject to certain factors including the ability of the Company’s contract research organization to collect, compile, and report data from the study.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| ADVANCED LIFE SCIENCES HOLDINGS, INC. |
| ||||||
|
|
|
|
|
| ||||
Dated: November 6, 2007 |
| By: |
| /s/ Michael T. Flavin |
|
| |||
|
| Name: |
| Michael T. Flavin, Ph.D. |
| ||||
|
| Title: |
| Chairman and Chief Executive Officer |
| ||||
|
|
|
|
|
| ||||
3